WebJul 1, 2024 · Shares of Citius Pharmaceuticals ( CTXR -0.99%), a clinical-stage biopharmaceutical company, are getting beaten down today after the company released disappointing news regarding its lead... WebApr 6, 2024 · CTXR Articles Average Week Source Sentiment All Sentiments This page (NASDAQ:CTXR) was last updated on 4/1/2024 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring
CTXR Stock Price Citius Pharmaceuticals Inc. Stock
WebApr 4, 2024 · Earnings Summary. For their last quarter, Citius Pharmaceuticals (CTXR) reported earnings of -$0.04 per share. This reflects a breakeven earnings surprise. Look out for CTXR's next earnings ... WebApr 11, 2024 · Citius Pharmaceuticals - CTXR Stock Forecast, Price & News $1.34 +0.17 (+14.53%) (As of 04/3/2024 04:00 PM ET) Compare Today's Range $1.17 $1.38 50-Day Range $0.98 $1.42 52-Week Range $0.77 $2.01 Volume 1.81 million shs Average Volume 843,413 shs Market Capitalization $195.99 million P/E Ratio N/A Dividend Yield … grand berry theater fort worth
Therapeutic Solutions International Inc. - MarketWatch
WebCitius Pharmaceuticals Inc. on Wednesday said it filed for U.S. Food and Drug Administration approval of its lead product candidate denileukin diftitox, also known as I/Ontak, for the treatment of... WebCitius Pharmaceuticals Inc. Quarterly balance sheet by MarketWatch. View all CTXR assets, cash, debt, liabilities, shareholder equity and investments. WebCTXR Citius Pharmaceuticals Inc. Profile MarketWatch Citius Pharmaceuticals Inc. company facts, information and financial ratios from MarketWatch. Citius … grandberry youtube